

**TABLE OF CONTENTS**

|   |           |
|---|-----------|
| <b>Welcome</b>                                      | <b>2</b>  |
| <b>Minister for Health &amp; Children</b>           | <b>3</b>  |
| <b>Message from Regional Oncology Director</b>      | <b>4</b>  |
| <b>Message from National Cancer Institute (NCI)</b> | <b>4</b>  |
| <b>Conference Programme</b>                         | <b>5</b>  |
| <b>The Cancer Strategic Development Award</b>       | <b>9</b>  |
| <b>Biographies</b>                                  | <b>10</b> |
| <b>Regional Oncology Programme Office (ROPO)</b>    | <b>26</b> |
| <b>Sponsors</b>                                     | <b>27</b> |

WELCOME



Welcome to **CANCER 2008**, the International Cancer Conference of St James's Hospital. This year we celebrate our 6th Anniversary and have assembled a high quality program with international renowned leaders coming together to highlight the latest developments and challenges that we face to deliver 21st Century Medicine to Cancer Patients. The theme of this year's conference is "**Striving for Success in Cancer Care**". This conference is a major step towards forging greater links with international colleagues throughout the community, tackling the challenge of providing better care and state of the art therapies for cancer patients.

The recent development of a Cancer Control Strategy, providing a road map for cancer service development and cancer research initiatives over the next 5-10 years is a welcome one and we look forward to the implementation of this exciting initiative.

We are now embracing the latest advances in medicine and science, investing in infrastructure and people to enable Ireland to take its place at the forefront of international developments in cancer care and cancer research. **CANCER 2008** will address these key issues in cancer strategy, cancer care and cancer research. It will identify the key priorities at a national level to allow implementation of the Cancer Control Strategy and identify how we can appropriately embed research within our health service. This showcase of national and international leaders will critically review the latest developments in cancer prevention, molecular medicine, cancer care, cancer clinical trials and palliative care.

I speak for all members of the Scientific and Organising Committees when I acknowledge the significant support of colleagues at St James's Hospital, the management and board of St James's Hospital, the Regional Oncology Programme Office and colleagues at Trinity College Dublin who have been integral to this initiative. The Scientific Committee have made such an excellent programme a reality. I also take this opportunity to acknowledge the generous contributions of our sponsors – in particular I would like to thank our principal sponsors The National Cancer Institute and the Irish Cancer Society for their continued support.

This Conference also contributes to the continuing development of the *Ireland Northern Ireland National Cancer Institute Cancer Consortium* (<http://www.allirelandnci.org>) and it is extremely encouraging to see the significant presence of key members of the National Cancer Institute and the Northern Ireland Cancer community at this meeting.

Our 6th Annual International Cancer Conference will showcase the best of cancer care and cancer research in Ireland, while bringing together international experts to contribute to our continual search for the best quality care for the Irish patient. St James's Hospital and Trinity College Dublin are committed to Cancer Care and Cancer Research; this conference represents a significant commitment to this aspiration. I am extremely enthusiastic about the quality of the program and look forward to meeting you all in Dublin.

A handwritten signature in black ink that reads "Mark Lawler". The signature is written in a cursive, flowing style.

Professor Mark Lawler



## MINISTER FOR HEALTH & CHILDREN



It is a very great pleasure to me to open the 6th International Cancer Conference at Dublin Castle. I would particularly like to acknowledge Prof Mark Lawler and the organising committee for organising this conference and in attracting such a distinguished panel of national and international speakers in cancer control. Their significant efforts are reflected in the breadth of expertise at the conference and in the specialised themes to be addressed.

I particularly wish to acknowledge the support and enthusiasm of the members from the National Cancer Institute in the United States who have made a significant contribution to the improvement of cancer services on both sides of the border, particularly in the facilitation of all Ireland participation in clinical trials. The links between Ireland and the United States have always been strong; many of our experts in cancer care services received their training in the United States. The Ireland/Northern Ireland/NCI Cancer Consortium has solidified this relationship by forging formal links providing the basis for a long-term partnership to improve cancer care delivery.

The theme of this year's conference is '**Striving for Success in Cancer Care**'. The programme promises to be very exciting as we examine the developments and challenges that we face to deliver 21st Century Medicine to Cancer Patients. Cancer clinical trials are crucial to the delivery of new and innovative medicines to cancer patients. Linking science and medicine, with the patient at the centre of the process also provides the impetus for discoveries from the laboratory to be fast-tracked to the clinic.

Ensuring that we find ways of consistently applying the knowledge derived from this research is a challenge for us all. The sharing of knowledge at major conferences such as this is an essential step in the transfer of knowledge to practitioners to encourage the developed of improved strategies and processes for the cancer patient. This is the necessary pathway to achieve our common objective to prevent and cure more cancers and continue to improve the prognosis of patients who cannot yet be cured. This is the major goal of the Government's National Cancer Control Strategy which is currently being implemented across the country.

I wish to take this opportunity to recognise the support of St James Hospital, its board and its chairman, Mr Tom Mitchell and Chief Executive Officer Mr Ian Carter as well as the medical and other staff for their support for Professor Tom Keane and his team as he takes on the challenge of implementing the National Cancer Control Programme which will help to create a uniform and high quality approach to all aspects of cancer control in Ireland.

I wish the conference every success and I hope that the speakers and participants alike and especially our visitors from abroad will enjoy their stay in our beautiful city.

Mary Harney T.D.,  
Minister for Health and Children



## REGIONAL ONCOLOGY DIRECTOR



It is my great pleasure to contribute this foreword for **CANCER 2008**, the 6th International Cancer Conference. The principal themes have remained consistent since the inaugural conference in 2003, these encompass a broad spectrum that includes national cancer strategy, the structures and processes underpinning clinical care, standards and quality assurance, cancer prevention and health promotion, clinical trials, and molecular research. We are privileged once again to have the participation of many distinguished experts from Europe and North America as well as national opinion leaders in oncology.

The success of the conference each year has been founded on the commitment and professionalism of a highly dedicated organising committee, and on the support of many individuals and groups from Ireland and abroad. We are especially indebted to our colleagues from the National Cancer Institute in Washington, Belfast City Hospital, and the Department of Health and Children. I would like to thank the Health Research Board and our friends in the voluntary sector, the Irish Cancer Society and the Marie Keating Foundation.

I would like to especially acknowledge Professor Mark Lawler for his vision and commitment to establishing an international conference, and acknowledge and thank Ms. Hilary Craig, the Regional Oncology Programme Office, for her meticulous organisation and planning. I would also like to acknowledge with sincere gratitude the Cancer Executive Committee of St. James's Hospital and current and previous senior administrators at St. James's Hospital, in particular Dr. Thomas Mitchell, Chairman of the Hospital Board.

The exigency for national reform in cancer services has never been more acute, and the inception of the National Cancer Control Programme represents a positive opportunity to raise standards and assure quality. The theme of **CANCER 2008** is resonant with many of the key current issues in Ireland. The organisers anticipate that discussion and debate from national and international experts will inform and stimulate the target audience of all on this island who have a responsibility and ambition to develop a national cancer programme that is underpinned by uniform high standards and achieves optimum outcomes.

Professor John Reynolds  
Regional Director, Cancer Services, Regional Oncology Programme Office

## NATIONAL CANCER INSTITUTE



Welcome to **CANCER 2008**, the International Cancer Conference of St James's Hospital in collaboration with the Regional Oncology Programme Office, Health Services Executive, The Irish Cancer Society and Trinity College Dublin. The National Cancer Institute has taken an active part in this programme since its inception and regards it as an important part of its Scholar Exchange Programme as part of the *Ireland Northern Ireland National Cancer Institute Cancer Consortium*.

**CANCER 2008** represents another important step in the Conference series which showcases cancer research and cancer care activity on the island of Ireland and facilitates the interactions between researchers on the island and those from around the world. The NCI is pleased to be able to participate again in 2008. An excellent Programme has been assembled and I look forward to participating in this Conference in Dublin Castle in May 2008.

Dr Joe Harford,  
National Cancer Institute



## WORKSHOP PROGRAMME

### WEDNESDAY 7TH MAY 2008

Cancer Clinical Trials in the Molecular Era sponsored by Pfizer Oncology and Roche

|  |                         |   |
|--|-------------------------|---|
| 9.00   |                         | <b>REGISTRATION</b>   |
| 9.45   |                         | Welcome and Opening of Workshop   |
|  | <b>Session I:</b>       | <b>“CLINICAL TRIALS AND THEIR RELEVANCE”</b>  |
|  | <b>Chairs:</b>          | <b>Dr Brian Moulton</b> , All Ireland Co-operative Oncology Research Group (ICORG)<br>Chairperson to be confirmed   |
| 9.50   | <b>Introduction</b>     | <b>Prof Mark Lawler</b> , Trinity College Dublin, Ireland   |
| 10.00  |                         | <b>Phase I Clinical Trials</b><br><b>Dr Richard Wilson</b> , Belfast City Hospital, Belfast, Northern Ireland   |
| 10.30  |                         | <b>Phase II/III - Clinical Trials</b><br><b>Prof John Crown</b> , St Vincent's University Hospital, Dublin, Ireland   |
| <b>11.00 COFFEE AND EXHIBITION/ POSTER VIEWING</b> |                         |   |
| 11.30  |                         | <b>Clinical Trials in Haematological Malignancies</b><br><b>Prof Shaun McCann</b> , St James's Hospital and Trinity College Dublin, Ireland   |
| 12.00  |                         | <b>Clinical Trials in the EU Directive Era</b><br><b>Ms Zoe Doran</b> , Guys Hospital, United Kingdom   |
| 12.30  |                         | <b>The Evolution of a Cancer Genetics Service in an Academic Teaching Hospital</b><br><b>Mr Michael Farrell</b> , St James's Hospital, Dublin, Ireland  |
| <b>13.00 LUNCH AND EXHIBITION/ POSTER VIEWING</b>  |                         |   |
|  | <b>Session II:</b>      | <b>CANCER CLINICAL TRIALS IN THE 21ST CENTURY</b>   |
|  | <b>Chairs:</b>          | <b>Dr Elizabeth Vandenberghe</b> , St James's Hospital, Dublin, Ireland<br><b>Dr Oscar Breathnach</b> , Beaumont and Royal College of Surgeons in Ireland   |
| 13.50  |                         | <b>Challenges in the Treatment of Pancreatic Cancer</b><br><b>Dr Ray McDermott</b> , Adelaide and Meath incorporating the National Childrens Hospital, Tallaght, Ireland  |
| 14.20  | <b>Special Lecture:</b> | <b>The Convergent Development of Molecular - Targeted Drugs for Cancer Treatment and Prevention</b><br><b>Prof Scott Lippman</b> , MD Anderson Cancer Centre, Houston, Texas, USA                               |
| 15.00  |                         | <b>Clinical Trials on the Island of Ireland</b><br><b>Dr John Kennedy</b> , St James's Hospital, Dublin, Ireland  |
| 15.30  |                         | <b>Risk Adapted Therapy using Clinical and Genetic Determinants for Children and Adolescents with Lymphoid Malignancies</b><br><b>Prof Owen Smith</b> , Our Ladys Children's Hospital, Crumlin, Dublin, Ireland |
| <b>16.00 COFFEE AND EXHIBITION/ POSTER VIEWING</b> |                         |   |
|  | <b>Session III:</b>     | <b>INTEGRATING TRANSLATIONAL RESEARCH INTO CLINICAL TRIALS</b>  |
|  | <b>Chairs :</b>         | <b>Dr Robert O'Connor</b> , Dublin City University, Ireland<br><b>Prof Patrick Johnston</b> , Queens University Belfast, Northern Ireland   |
| 16.30  |                         | <b>Clinical Trials of Mitochondria Targeted Therapy in Thoracic Cancers</b><br><b>Dr Dean Fennell</b> , Queens University, Belfast, Northern Ireland  |
| 17.00  |                         | Keynote Address - <b>Title to be confirmed</b>  |
| 17.50  |                         | <b>Prof Rick Kaplan</b> , National Cancer Research Network, Leeds, United Kingdom   |
|  | <b>END OF DAY 1</b>     |   |

## PROGRAMME

THURSDAY 8TH MAY 2008  
Dublin Castle

|                                |   |
|--------------------------------|---|
| 8.45                           | <b>REGISTRATION FOR CANCER 2008</b><br>COFFEE AND EXHIBITION/POSTER VIEWING   |
| <b>Session IV:<br/>Chairs:</b> | <b>STRATEGIC DIRECTIONS IN CANCER</b><br>Dr Maccon Keane, University College Hospital, Galway, Ireland<br>Dr Marie Laffoy, Health Services Executive, Dublin, Ireland                               |
| 9.30                           | <b>Message from the National Cancer Institute</b><br>Dr Joe Harford, National Cancer Institute, USA   |
| 9.45                           | <b>Strategic Directions in Cancer, Learning from the NCRN Experience</b><br>Prof Rick Kaplan, National Cancer Research Network, Leeds, United Kingdom   |
| 10.30                          | <b>The National Program for Radiation Oncology (NPRO) – A work in progress</b><br>Prof Donal Hollywood, St Lukes Hospital and Institute of Molecular Medicine, St James's Hospital, Dublin, Ireland |
| <b>11.10</b>                   | <b>COFFEE AND EXHIBITION/ POSTER VIEWING</b>  |
| <b>Session V:<br/>Chairs:</b>  | <b>CANCER PREVENTION</b><br>Dr Harry Comber, Director of National Cancer Registry, Ireland<br>Ms Norma Cronin, Irish Cancer Society, Ireland  |
| 11.35                          | <b>The Contribution of Infectious Agents to the Global Burden of Cancer</b><br>Dr Joe Harford, National Cancer Institute, Washington, USA   |
| 12.10                          | <b>Strategies for Smoking Prevention</b><br>Dr Kenneth O'Byrne, St James Hospital, Dublin, Ireland  |
| <b>12.40</b>                   | <b>LUNCH AND EXHIBITION/ POSTER VIEWING</b>   |
| <b>Session VI:<br/>Chairs:</b> | <b>CANCER CARE - HOW ARE WE DOING?</b><br>Dr Seamus O Reilly, Cork University Hospital<br>Dr Paul Browne, St James's Hospital Dublin, Ireland   |
| 13.40                          | <b>Developing an All-Ireland Institute for Hospice and Palliative Care</b><br>Prof David Clarke, Lancaster University, United Kingdom   |
| 14.10                          | <b>Title to be confirmed</b><br>Dr Jon Billings, Health Services Executive, Dublin, Ireland   |
| 14.40                          | <b>Quality Assurance in Cancer Surgery</b><br>Prof John Reynolds, St James's Hospital and Trinity College Dublin, Ireland   |
| 15.10                          | <b>Cancer Care, the Netherlands Experience</b><br>Prof Hugo Tilanus, Erasmus University Medical Centre, Rotterdam, The Netherlands  |
| <b>15.40</b>                   | <b>COFFEE AND EXHIBITION/ POSTER VIEWING</b>  |



## PROGRAMME

### 16.00 OFFICIAL OPENING OF CONFERENCE

**Opening Address** Dr Thomas Mitchell, Chairperson, St James's Hospital  
Ms Mary Harney, Minister for Health & Children

**Session VII  
Chair:** **CANCER STRATEGIC DEVELOPMENT AWARD LECTURE**  
Prof Mark Lawler, St. James' Hospital and Trinity College Dublin, Ireland

16.30 **The Future for Cancer Medicine**  
Prof Patrick Johnston, Queens University Hospital, Belfast, Northern Ireland

**Session VIII:  
Chairs:** **INFLAMMATION AND CANCER**  
Prof Dermot Kelleher, Trinity College Dublin, Ireland  
Prof Noel Lowndes, National University of Ireland, Galway, Ireland

17.10 **Helicobacter Pylori and Cancer**  
Prof Colm O'Morain, Adelaide and Meath incorporating the National Childrens Hospital, Tallaght, Dublin, Ireland

17.40 **Regulatory T Cell Subversion of Anti-tumor Immunity and Their Manipulation in Cancer Immunotherapy**  
Prof Kingston Mills, Trinity College Dublin, Ireland

**Session IX:  
Chair:** **STATE OF THE ART LECTURE**  
Prof John Reynolds, St James's Hospital and Trinity College Dublin, Ireland

18.20 **Molecular Insights on the Pathogenesis of Oesophageal Cancer**  
Dr Rebecca Fitzgerald, University of Cambridge, United Kingdom

19.10 **END OF DAY 2**

### 20.00 RECEPTION

Hosted by the Department of Health & Children, St. Patrick's Hall, Dublin Castle. Address by Prof Dermot Kelleher Head of School of Medicine and Vice Provost for Medical Affairs, TCD

## PROGRAMME

### FRIDAY 9TH MAY 2008 Dublin Castle

8.15 **REGISTRATION**  
COFFEE AND EXHIBITION/ POSTER VIEWING

**Session X:  
Chairs:** **DEFINING QUALITY IN BREAST CANCER CARE**  
Prof Arnold Hill, Beaumont and Royal College of Surgeons in Ireland  
Mr Terry Boyle, St James's Hospital, Dublin, Ireland

8.45 **Title to be confirmed**  
Dr Ann O'Doherty, BreastCheck, Ireland

9.15 **The Surgeon and Breast Cancer: Quality is the Key**  
Mr James Geraghty, Adelaide and Meath incorporating the National Children's Hospital, Dublin, Ireland

9.45 **The Role of Pathology in Breast Cancer Care in the 21st Century**  
Dr Barbara Dunne, St James's Hospital, Dublin, Ireland

### 10.15 COFFEE AND EXHIBITION/ POSTER VIEWING

## PROGRAMME

FRIDAY 9TH MAY 2008

Dublin Castle

|       |  |   |
|-------|--|---|
|       | <b>Session XI:</b>                           | <b>UNDERSTANDING BIOLOGY, UNDERSTANDING CANCER</b>  |
|       | <b>Chairs:</b>                               | Prof Cormac Taylor, University College Dublin, Ireland<br>Dr Graham Pidgeon, Trinity College Dublin, Ireland  |
| 10.45 |  | <b>Development and Cancer: The HOX Gene Connection</b><br>Prof Terry Lappin, Queens University Belfast, Northern Ireland  |
| 11.20 |  | <b>Epigenetics and Cancer, the Importance of Polycomb Genes</b><br>Prof Marten Van Lohuizen, The Netherlands Cancer Institute, Amsterdam, Netherlands                         |
|       | <b>Session XII:</b>                          | <b>KEY NOTE ADDRESS -</b>   |
|       |  | <b>Irish Cancer Society Lecture</b>   |
|       | <b>Chair:</b>                                | Mr John McCormack, CEO, Irish Cancer Society  |
| 12.00 |  | <b>The Dilemma and Promise of Cancer Chemoprevention</b><br>Prof Scott Lippman, MD Anderson Cancer Centre, Houston, USA   |
| 12.45 | <b>LUNCH AND EXHIBITION/ POSTER VIEWING</b>  |   |
|       | <b>Session XIII:</b>                         | <b>STATE OF THE ART LECTURE</b>   |
|       | <b>Chair:</b>                                | Ms Ann Broekhaven, CEO, St Lukes Hospital Dublin, Ireland   |
| 13.45 |  | <b>Improving Palliative Care for Cancer</b><br>Dr Kathy Foley, Sloan Kettering Cancer Centre, New York, USA   |
|       | <b>Session XIV:</b>                          | <b>MOLECULAR MEDICINE AND CANCER</b>  |
|       | <b>Chairs:</b>                               | Prof Cliona O'Farrelly, Trinity College Dublin, Ireland<br>Prof David Lloyd, Trinity College Dublin, Ireland  |
| 14.30 |  | <b>Update on the Molecular Biology of Gynaecological Cancer</b><br>Prof John O'Leary, Coombe Womens Hospital and Trinity College Dublin                                       |
| 15.00 |  | <b>Cell Survival Strategies used by Tumour Cells</b><br>Prof Tom Cotter, University College Cork, Ireland   |
| 15.30 |  | <b>Hepatitis C Virus and Hepatocellular Carcinoma</b><br>Dr Laura Beretta, Fred Hutchinson Cancer Centre, Seattle, USA  |
| 16.15 | <b>COFFEE AND POSTER VIEWING</b>             |   |
| 16.45 |  | <b>Therapeutic Potential of Targeting CXC-Chemokines within the Tumour Microenvironment of Prostate Cancer</b><br>Dr David Waugh, Queens University Belfast, Northern Ireland |
|       | <b>Session XV:</b>                           | <b>STATE OF THE SCIENCE LECTURE</b>   |
|       | <b>Chair:</b>                                | Prof Liam Gallagher, University College Dublin, Ireland   |
| 17.15 |  | <b>The Value of Proteomics to the Clinical Perspective in Cancer</b><br>Dr Sam Hanash, Fred Hutchinson Cancer Research Centre, Seattle USA                                    |
| 18.00 | <b>CONCLUDING REMARKS AND END OF MEETING</b> |   |



## THE CANCER STRATEGIC DEVELOPMENT AWARD

The Cancer Strategic Development Award, which is linked to the International Cancer Conference of St James's Hospital aims to recognise an individual or group of individuals who have made a significant strategic contribution in the area of cancer care, cancer prevention, cancer research or cancer related healthcare issues on the island of Ireland.

Prof Patrick Johnston



It is with great pleasure that we announce that Prof Patrick Johnston has been chosen as the recipient of the **4th Cancer Strategic Development Award** for his contribution to the development of cancer care and cancer research on the island of Ireland. His pioneering role in the establishment of the *Ireland Northern Ireland National Cancer Institute Consortium*, together with his scientific leadership in the establishment of both the Clinical Cancer Centre at Belfast City Hospital and the Centre for Cancer Research and Cellular Biology at Queens University Belfast are shining beacons of the type of strategic drive that is required to provide world class centres in cancer care and cancer research on this island.

Minister Micheal Martin



The Cancer Strategic Development Award was established in 2005 and previous recipients of the award were:

**2005:** *Minister Micheal Martin*, TD, for his role while Minister of Health and Children in promoting cancer prevention by the introduction of the Smoking Ban on 29th March 2004. The recognised success of the Smoking Ban in Ireland has prompted other European countries to implement similar legislation, placing Ireland at the core of a significant international health care strategic development.

Prof Edison Liu



**2006:** *Prof Edison Liu* (currently Executive Director, Genome Institute of Singapore) for his role in helping to establish the *Ireland Northern Ireland National Cancer Institute Consortium* while Deputy Director of the National Cancer Institute. The Ireland Northern Ireland National Cancer Institute Memorandum of Understanding was signed in Stormont Castle in Belfast in 1999, leading to a series of initiatives in cancer care, cancer clinical trials, cancer education and cancer prevention which have generated significant benefit for the Cancer community on the island of Ireland

Prof Peter Daly



**2007:** *Prof Peter Daly*, Consultant Oncologist at St James's Hospital and Associate Professor of Oncology at Trinity College Dublin for his significant contribution to the development of oncology services, oncology research and oncology training on the island of Ireland. He was a member of the 1st and 2nd Fora on Development of Cancer Services in Ireland. He was a founding member of ICORG, the Irish Clinical Oncology Research Group. He served on the first committee of the NCI / Ireland / Northern Ireland Cancer Consortium. He also played a pivotal role in the establishment of adult genetic cancer services in Ireland.

## BIOGRAPHIES

Prof John Crown

**“Phase II/III - Clinical Trials”**

John Crown is a Consultant Medical Oncologist with St. Vincent's University Hospital and St. Luke's Hospital in Dublin, Ireland. In November 2003, he was awarded the Thomas Baldwin Research Chair in Translational Cancer Research from Dublin City University and in December 2004 was awarded the Newman Clinical Research Professorship in the School of Medicine of University College Dublin. Professor Crown is a founding member and leader of many organizations that include the Irish Clinical Oncology Research Group, the Anglo-Celtic Oncology Group, the European Breast Cancer Dose Intensity Study, and the Irish Society of Medical Oncology. Professor Crown chairs the Breast Committee of the Irish Clinical Oncology Research Group (ICORG). Professor Crown received his medical training at UCD and the State University of New York. Professor Crown went on to complete his fellowship training in oncology at Mount Sinai Medical Centre and in haematology/oncology at Memorial Sloan Kettering Cancer Centre. He served as assistant professor at Cornell University Medical College before joining St. Vincent's University Hospital in 1993.

Prof Shaun McCann

**“Clinical Trials in Haematological Malignancies”**

Professor of Academic Medicine and Director of Teaching and Learning Trinity College Dublin. In 1983 appointed as Consultant Haematologist to St James's Hospital. He established a National Stem Cell Transplant Unit for Leukaemia and related disorders and carried out the first successful Stem Cell Transplant in Ireland in 1984. A Translational Research Laboratory was established in conjunction with the National Stem Cell Transplant Unit in St James's Hospital. Since then the unit has carried out > 1000 Stem Cell Transplants. Professor McCann is the author of >150 peer reviewed publications, numerous book chapters and a textbook of Haematology for undergraduate medical students. The John Durkan Leukaemia Research Laboratories were opened in St James's Hospital in 2003. He was inaugural President of the Haematology Association of Ireland. Special interests include Stem Cell Transplantation, Infection in the treatment of Haematological Malignancies, Aplastic Anaemia, Chronic Myeloid Leukaemia and undergraduate teaching.

Ms Zoë Doran

**“Clinical Trials in the EU Directive Era”**

Zoë Doran qualified as a State Registered Nurse in Ireland in 1980 and spent the next 5 years gaining clinical experience in paediatrics, oncology, cardiology and interventional radiography in hospitals in Ireland and the UK. In 1985 she joined the Imperial Cancer Research Fund's Breast Unit at Guy's Hospital, initially as a Research Nurse/Trial Coordinator, taking over as Research Manager 18 months later. In 1990, she was recruited into the Pharmaceutical Industry, joining Schering-Plough Corporation, based in their UK subsidiary, transferring to their International Headquarters in the US in 1994. After 7yrs in Industry she returned to hospital based trials and was recruited to the position of Assistant Director at the Kaplan Comprehensive Cancer Centre in NYC with the remit of re-establishing the NCI core grant funding for Research Nursing and Data Management. Returning to Ireland in 2000, she spent the next



## BIOGRAPHIES

Ms Zoë Doran  
continued

Prof Scott Lippman

Dr John Kennedy



Prof Owen Smith



five years working initially in Clinical Trials Management and latterly on a project to develop regional oncology referral and treatment guidelines for the SW Dublin Regional Oncology Programme.

### **“The convergent development of molecular- targeted drugs for cancer treatment and prevention”**

Chair and Professor, Charles A. LeMaistre Distinguished Chair in Thoracic Oncology, Thoracic/Head & Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX . Dr. Lippman focuses his research on the translational study of risk, biology and prevention of carcinogenesis at various organ sites, primarily the head and neck, lung and prostate. He also is interested in mechanistic studies of polyunsaturated fatty acid metabolic pathways and potential targets in these pathways for drug development. He has elucidated the convergence of prevention and therapy in molecular targeted drug development.

### **“Clinical Trials on the Island of Ireland”**

Dr. Kennedy holds the position as Consultant Medical Oncologist at St James's Hospital and St. Lukes Hospital and Director of the Cancer Clinical Trials Consortium at St James's Hospital. Dr. Kennedy holds a Bachelor of Medicine, a Bachelor of Surgery and a Bachelor of Obstetrics from the University of Dublin, Trinity College where he was awarded a first class degree and won the university Gold Medal in 1983. His training took him from Ireland to the United States where he began a Clinical Fellowship in Oncology at the renowned Johns Hopkins University in Baltimore in 1987 and rose to the position of Associate Professor of Oncology before returning to Ireland in 1998. He is the Vice Chairman of the Irish Clinical Oncology Research Group (ICORG), immediate past Chairman of the Irish Society for Medical Oncology, and Chairman of the Medical Committee of the Irish Cancer Society. His major research interest is in breast cancer.

### **“Risk adapted therapy using clinical and genetic determinants for children and adolescents with lymphoid malignancies”**

Professor Smith is a Consultant Paediatric Haematologist, at Our Lady's Hospital for Sick Children, Dublin, and is Professor of Haematology at Trinity College Dublin. His active research areas of interest include: childhood leukaemia, bone marrow failure syndromes; the molecular and cellular basis of the inflammatory - coagulation interface in human disease. The co-author of more than 290 research articles, letters, abstracts, books, book chapters and papers, Prof. Smith is a Fellow of the Royal College of Pathologists, the Royal College of Physicians of Dublin, London, Glasgow, Edinburgh and the Royal College of Paediatrics and Child Health. He was awarded the Graves Medal by the Royal Academy of Medicine and Health Research Board in 2001 for his research into the pathobiology and novel therapeutic strategies in severe sepsis that had received international acclaim. In 2006, Professor Smith was awarded the St Luke's Medal by the Royal Academy of Medicine and St Luke's Hospital for his work on improving outcomes in adolescent cancers with specific reference to leukaemia.

## BIOGRAPHIES

Dr Dean Fennell

**“Clinical Trials of Mitochondria Targeted Therapy in Thoracic Cancers”**

Dean Fennell qualified with a first class degrees in Pharmacology followed by Medicine and Surgery from University College London in 1993. Basic specialist training at the UCL, Hamersmith, Brompton, Guy's and St Thomas' Hospitals in London led to Membership of the Royal College of Physicians in 1996, followed by a PhD in Oncology as a Medical Research Council fellow, focusing on BCL-2 family protein targeted apoptosis sensitizers. This was followed by specialist training in Medical Oncology at St Bartholomew's Hospital, and in 2005, he was awarded a Cancer Research UK Clinician Scientist fellowship as a Consultant and Senior Lecturer in Medical Oncology, based at the Centre for Cancer Research and Cell Biology, Queen's University Belfast. His specialist area is thoracic oncology and early clinical trials, with a particular interest in therapeutic targeting of the intrinsic apoptosis pathway. He has established the first comprehensive, novel agent clinical trials portfolio for thoracic cancers in Northern Ireland. Dr Fennell leads a CR-UK funded research group with focus on mitochondria targeted therapeutics. Dr Fennell led NTRAC until 2006 and is now on the steering committee for the CR-UK Experimental Medicine Cancer Centre in Belfast. In 2007 Dr Fennell was elected to fellowship of the Royal College of Physicians.

Prof Richard Kaplan

**“Strategic Directions in Cancer, learning from the NCRN Experience”**

Prof Richard Kaplan is Associate Director of the National Cancer Research Network (NCRN) and Professor of Clinical Cancer Studies at the University of Leeds. He is also Associate Director of the UK Clinical Research Network. Prof. Kaplan is a medical oncologist with 30 years in clinical research in the US and has been Chief, Clinical Investigations Branch, National Cancer Institute, National Institutes of Health. He was Program Director for the NCI's national program of Cooperative Group clinical trials of cancer treatments, and Program Director for NCI's Brain Tumor Consortia. He has been responsible for scientific coordination of NCI-funded or -sponsored treatment trials in brain, urological, and gastrointestinal malignancies, and has served on advisory committees and panels for NCI, NIH, FDA and for other government agencies and professional organizations, as well as for clinical trials networks in the UK, Ireland, and Europe. The National Cancer Research Network (NCRN) is a managed research network mapping directly onto the NHS cancer service networks across England. Funding for NCRN supports the provision of research nurses, data managers and the expertise of clinicians, radiologists, pharmacists and pathologists.

Dr Joe Harford

**“The Contribution of Infectious Agents to the Global Burden of Cancer”**

Dr. Joe Harford received a Ph.D. in Biochemistry from the University of Maryland Medical School and conducted basic research in molecular biology and cell biology at the National Institutes of Health from 1979 to 1993 rising to be Deputy Branch Chief of the Cell Biology and Metabolism Branch within NICHD. In 1993, Dr. Harford became the chief scientist for RiboGene, Inc., a then-privately-held biotechnology company. There, he managed four drug discovery programs in infectious diseases and cancer that collectively received more NIH



## BIOGRAPHIES

Dr Joe Harford  
continued

SBIR grant funding in FY1996 than any other drug discovery company in the Nation. He participated in raising venture capital and in negotiations that culminated in an alliance with a major pharmaceutical company and eventually an initial public offering for RiboGene. From 1996 to 1999, Dr. Harford served as Chairman of the Scientific Advisory Board of RiboGene, Inc, and now serves in a similar capacity for SynerGene Therapeutics, Inc., an early-stage biopharmaceutical company that focuses on molecular therapeutics for cancer. In 1996, Dr. Harford returned to the NIH where he served as Associate Director of the NCI and Chief of Staff of the Office of the Director, a diverse group of offices with responsibilities that include preparation of the NCI budget, press relations, and interactions with the U.S. Congress, patient advocacy groups and professional organizations. Dr. Harford also served as the NCI liaison to the National Cancer Policy Board of the National Academy of Sciences. Currently, Dr. Harford is the Chair of NCI's Technology Review Group, responsible for review of employee inventions and recommendations for actions taken regarding patent strategy for technology transfer activities. In July 2002, Dr. Joe Harford was named Director of the Office of International Affairs of the National Cancer Institute. In this capacity, he has responsibility for a number of bilateral and multilateral interactions between the NCI and foreign cancer research institutions and other foreign entities. Dr. Harford serves as the Chair of the Strategic Advisory Group of the *Ireland Northern Ireland National Cancer Institute Cancer Consortium*. In July 2006, Dr. Harford was named as Strategic Leader for Knowledge Transfer by the International Union Against Cancer (UICC) and in this capacity serves on the UICC Strategic Coordinating Committee.

Prof Donal Hollywood



### **“The National Program for Radiation Oncology (NPRO) – A work in progress”**

Professor Donal Hollywood is the Marie Curie Professor of Clinical Oncology at Trinity College Dublin and the Head of the Academic Unit of Clinical and Molecular Oncology at the College. He trained in Oncology at the Hammersmith Hospital and ICRF Molecular Oncology Unit, London and subsequently as a Fulbright Scholar at Baylor College of Medicine, Houston. Since his appointment to Trinity College Dublin he has held elected positions on the Board of Trinity College Dublin, the Faculty of Radiologists (RCSI), and the Education Board of the Royal College of Radiologists (RCR) in London. He was Chairperson of the National Expert Group on Radiation Oncology and is currently the Chairperson of the National Radiation Oncology Coordinating Group (NCROG) and a member of the National Cancer Forum.

Dr Kenneth O'Byrne



### **“Strategies for Smoking Prevention”**

Dr Kenneth O'Byrne is a Consultant Medical Oncologist with a particular interest in the management of thoracic malignancies. He is clinical director of the HOPE directorate at St James's Hospital and a clinical lecturer at Trinity College, Dublin. Dr. O'Byrne qualified from University College, Dublin (UCD) in 1984, completed his higher professional training in oncology at the Churchill Hospital, Oxford in 1997 and subsequently worked as a consultant and senior lecturer in medical oncology at the University Hospitals of Leicester NHS Trust and University of Leicester until October '03 before returning to Dublin in November '03. He is a founder member of the British Thoracic

## BIOGRAPHIES

Dr Kenneth O'Byrne  
continued

Oncology Group (BTOG) and British Mesothelioma Interest Group (BMIG) and sits on the UK National Cancer Research Institute Lung Clinical Studies Group committee. Since returning to Dublin, Dr O'Byrne has set up the Thoracic Oncology Research Group based within the Clinical Trials Unit and the Institute of Molecular Medicine on the St James's Hospital Campus with an interest in carcinogenesis, identification of novel biomarkers and novel targeted therapy in lung cancer and mesothelioma.

Prof David Clarke



**“Developing an All-Ireland Institute for Hospice and Palliative Care”**

David Clark was educated at the Universities of Newcastle-upon-Tyne, England and Aberdeen, Scotland. Whilst working at the MRC Medical Sociology Unit in Aberdeen in the early 1980s, he began to develop an interest in the sociological aspects of health and illness, which has now become his major research focus. He was appointed Professor of Sociology at Sheffield Hallam University in 1993 and in 1995 became Professor of Medical Sociology at the University of Sheffield, and Associate Director of Trent Palliative Care Centre. In September 2003 he joined Lancaster University as Professor of Medical Sociology and Director of the International Observatory on End of Life Care; he was Director of the Institute for Health Research at Lancaster from January 2005 - July 2006. He is currently engaged in a number of studies concerned with service evaluation relating to the provision of end of life care and with issues of policy development, the international growth of palliative care and related ethical issues. In 2005, with support from the Irish Hospice Foundation, he took up the position of Visiting Professor in Hospice Studies at Trinity College Dublin and University College Dublin.

Mr Jon Billings

**“Title to be confirmed”**

Jon Leads the Authority's Healthcare Quality Directorate. He and his team will be responsible for setting and monitoring standards for quality and safety in Ireland's Healthcare services; implementing continuous quality assurance and patient safety programmes and undertaking investigation into serious concerns as required. His lifetime career in healthcare has seen Jon hold a number of senior posts including head of healthcare strategy and development at the UK's Audit Commission, the main public spending regulator in England. He joined the Healthcare Commission in 2005 as regional manager for the London and South East Region, managing a team of eighty people undertaking registration, inspection and assessment of NHS and private sector providers. Latterly, he was the Commission's Head of Independent Healthcare, responsible for national policy for the regulation of private sector healthcare. Jon obtained an MBA from the University of Kent in 1996.

Prof John Reynolds



**“Quality Assurance in cancer surgery”**

Professor John V. Reynolds is Professor of Surgery and Head of Department at Trinity College Dublin. He took up this position in July 2001. He is a specialist oesophageal and gastric surgeon and is based at St James's Hospital. He is the regional director of cancer services in the south-west area of the Eastern Regional Health Authority. His clinical and research training involved periods at the University of Pennsylvania, Philadelphia, the Memorial Sloan-



## BIOGRAPHIES

**Prof John Reynolds**  
continued

Kettering Cancer Centre in New York, and St Mary's Hospital, London. He was consultant oesophageal surgeon and senior lecturer in St James's University Hospital in Leeds before returning to Dublin in 1997. His research interests are in molecular understanding of Barrett's oesophagus and oesophageal cancer, the molecular prediction of response or resistance to chemotherapy and radiation therapy, obesity and cancer, and modulating the immune response following complex major surgery.

**Prof Hugo Tilanus**

### “Cancer Care, the Netherlands Experience”

Hugo W. Tilanus, Professor of Surgery, born in 1948 attended Leiden Medical School and obtained his medical degree in 1976. After a research fellowship of one year at the Laboratory of Experimental Surgery from the Erasmus University, he was trained as a surgeon at the Erasmus Medical Centre Rotterdam from 1978 till 1984. In 1983 he obtained his PhD. from the Erasmus University Rotterdam for his thesis ‘The femoropopliteal bypass’. From 1984 till 1997 he developed his surgical career with special interest in the treatment of carcinomas of the oesophagus and in liver transplantation in the same institution. His clinical work is mirrored in his scientific interests. In 1997 he was appointed as full Professor of Surgery at the Erasmus University Rotterdam with special interest in ‘upper abdominal surgery and liver transplantation. Currently he fulfils several functions in and outside the Erasmus University Medical Centre. Among others he is deputy chairman of the Department of Surgery, chairman of the Medical Ethical Committee and he is a member of the editorial board of several surgical journals.

**Dr Thomas Mitchell**

Chairman of the Board, St. James's Hospital. Thomas N. Mitchell, born in Co. Mayo, completed his BA at UCG in 1961 and his PhD at Cornell University in the US. He was appointed Chair in Classics in Swarthmore in 1978. The following year he returned to Ireland to assume the Chair of Latin at Trinity College. He was elected a Fellow of Trinity College in 1980 and went on to hold office as Senior Dean and Senior Lecturer before being elected Provost in 1991. He was appointed Chairman of the Board at St. James's Hospital in 2002.

**Mr Ian Carter**

Mr Carter is currently the Chief Executive Officer at St James's Hospital which is a 998 bed academic teaching hospital in Ireland. Prior to this he has held senior hospital management positions within Ireland - Deputy CEO, St James's Hospital, General Manager, Acute Hospitals, Mid Western Health Board; England - Directory of Contracts and Business Administration, 1st Wave Hospital Trust - Regional Surgical Specialties Manager; Saudi Arabia - Assistant Hospital Manager. For the last 7 years, Mr Carter has also held the post of Associate Lecturer, National College of Ireland, with specific areas of interest in Organisational Behaviour Management Theory.

**Prof Colm O'Morain**



### “Helicobacter Pylori and Cancer”

Colm O'Morain is Professor of Medicine at The Adelaide and Meath Hospital, Dublin incorporating the National Children's Hospital. He is the Dean of the Faculty of Health Sciences, Trinity College Dublin. He received his postgraduate education in Nice, London and New York. He is the Chairman of the United European Gastroenterology Federation Public Affairs Committee. He is a founder member of the

## BIOGRAPHIES

Prof Colm O'Morain  
continued

European Board of Gastroenterology. He is the immediate past President of the European Societies of Gastroenterology. He is a Consultant Gastroenterologist at The Adelaide and Meath Hospital, Dublin incorporating the National Children's Hospital. He is a member of the Hospital Board at Tallaght Hospital and the Meath Foundation. His research interests are in *Helicobacter pylori*, inflammatory bowel disease, and screening and early detection of gastrointestinal cancer.

Prof Kingston Mills

**“Regulatory T cell subversion of anti-tumor immunity and their manipulation in cancer immunotherapy”**

Kingston Mills is The Professor of Experimental Immunology and Head of Immunology in the School of Biochemistry and Immunology, Trinity College Dublin. He graduated from Trinity College and trained as a Postdoctoral Fellow at University College Hospital London and the National Institute for Medical Research, Mill Hill, London, before joining the Scientific Staff of the National Institute for Biological Standards and Control in Herts, UK. He returned to Ireland in 1993 to take up an academic position at National University of Ireland, Maynooth, where he was Director of The Institute of Immunology. He was appointed to a Personal Chair at Trinity College Dublin in 2001. In the same year he was awarded a Science Foundation Ireland Principal Investigator Research Award. He heads an active research team of over 20 scientists with a research focus on the immunology of infectious diseases and cancer, immune regulation, adjuvants and vaccines.

Dr Rebecca Fitzgerald



**“Molecular insights on the pathogenesis of oesophageal cancer”**

Rebecca Fitzgerald received her Medical training at Cambridge University UK and then went to research at Stanford University, USA and worked with George Triadafilopoulos, an oesophageal cancer specialist at Stanford. She returned to the UK and worked as a postdoctoral fellow at Barts and The Royal London Hospital. In 2004, she won the Westminster Medal in 2004 for communicating her work to politicians and the public. In 2007 she received the Sir Francis Avery Jones Medal and was appointed Goulstonian Lecturer by the Royal College of Physicians and the Academy of Medical Sciences for 2007. She is currently the Group Leader at the MRC Cancer Cell Unit, Hutchison-MRC Research Centre in Cambridge. Her group are using genetic epidemiology tools to identify low penetrance genetic variants that may be common in the population and, hence, in combination with exposure to environmental factors may predispose to Barrett's oesophagus, and oesophago-gastric adenocarcinoma.

Mr. James Geraghty

**“The Surgeon and Breast Cancer: Quality is the Key”**

Mr. Geraghty is Consultant Surgeon with a special interest in Breast Diseases at the Adelaide and Meath Hospital incorporating the National Children's Hospital in Dublin (AMNCH). He is Clinical Director of the AMNCH Breast Unit, and is also Chairman of the Hospital's Cancer Strategy Committee. Prior to returning to Dublin, Mr. Geraghty was Consultant Surgeon in the Nottingham Breast Institute and prior to that was Clinical Director of Surgery at the European Institute of Oncology in Milan, Italy. His major research interest is in Genetic Risk Assessment for Breast Cancer in which a Research Programme has been established jointly with the Smurfit Institute of Genetics in Trinity College, Dublin. He has major interests



## BIOGRAPHIES

**Mr. James Geraghty**  
continued

in educational training in oncology and has in the past been the Programme Director at the European School of Oncology in Milan as well as Chairman of the Education and Training Committee of the European Society of Surgical Oncology. He is a recipient of the James IV Association of Surgeons Travelling Fellowship, The Royal College of Surgeons Travelling Fellowship, The Millin Medal as well as an Ainsworth Scholarship.

**Dr Barbara Dunne**



### **“The role of pathology in breast cancer care in the 21st century”**

Dr. Dunne was appointed consultant pathologist and lead breast pathologist at St James Hospital in 2004. Prior to that she was a consultant at the Western Infirmary, Glasgow and at the West of Scotland Breast Screening Centre. In addition to breast pathology, she is also involved in the provision of specialist pathology services in haematopathology and urological pathology at St James. Her research interests include metaplastic breast cancer and familial breast cancer.

**Prof Terry Lappin**

### **“Development and Cancer: The HOX Gene Connection”**

Professor Terry Lappin graduated in chemistry from Queen's University, Belfast and received his PhD in biochemistry in 1975. He spent two sabbatical periods with Professor Eugene Goldwasser at the University of Chicago working on erythropoietin. Appointed to the Chair of Haematology at Queen's University Belfast in 1997, he is currently Deputy Director of the Centre for Cancer Research and Cell Biology at Queens University Belfast. He is Scientific Secretary of the British Society for Haematology. His main research interests are in erythropoietin, its receptor and the role of homeobox (HOX) genes in cancer. Based on the hypothesis "Oncology recapitulates ontology" his group investigates genes that are normally only active during embryonic development but are re-expressed in neoplasia.

**Prof Maarten van Lohuizen**

### **“Epigenetics and cancer, the importance of polycomb genes”**

Maarten van Lohuizen is head of the Division of Molecular Genetics, The Netherlands Cancer Institute, Amsterdam and is Professor at the University of Amsterdam Medical School (From 2007). After a postdoctoral period (UCSF, I. Herskowitz) he has been a group leader at The Netherlands Cancer Institute, Amsterdam (from 1995). His group has made important contributions on the functional analysis of epigenetic gene silencing mechanisms by Polycomb-group protein complexes, which play crucial roles in controlling development, differentiation and cell proliferation and when deregulated contribute to cancer formation. His group has also developed genome wide genetic screens in cell-based assays (using RNAi library technology) and in cancer-prone mice to identify new genes that contribute to cancer and classify them in functional groups/signaling pathways. In addition, his group has recently demonstrated a crucial role for Bmi1/Pc-G protein complexes in maintaining hemopoietic, neuronal and embryonal stem cell fate and has implicated the Sonic Hedgehog (Shh) morphogen as a regulator of Bmi1 expression in neuronal precursor cells Unraveling the role of Bmi1/Pc-G in stem cell fate versus differentiation decisions and the consequence of this for cancer (stem) cell biology is currently a major focus of the group.

## BIOGRAPHIES

Dr Kathy Foley

**“Improving Palliative Care for Cancer”**

Dr. Kathleen M. Foley is an Attending Neurologist in the Pain & Palliative Care Service at Memorial Sloan-Kettering Cancer Center in New York City and is also Professor of Neurology, Neuroscience, and Clinical Pharmacology at Weill Medical College of Cornell University, and previous Director of the WHO Collaborating Center for Cancer Pain Research and Education at Memorial Sloan-Kettering Cancer Center. She holds the Chair of the Society of Memorial Sloan-Kettering Cancer Center in Pain Research. She was elected to the Institute of Medicine of the National Academy of Sciences for her national and international efforts in the treatment of patients with cancer pain. She is the past Director of the Project on Death in America of the Open Society Institute whose goal was to transform the culture of dying in the United States through initiatives in research, scholarship and clinical care. Dr. Foley is currently the Medical Director of the International Palliative Care Initiative of the Network Public Health Program of the Open Society Institute working to advance palliative care globally. Dr. Foley has focussed her career on the assessment and treatment of patients with cancer pain. With her colleagues, she has developed scientific guidelines for the use of analgesic drug therapy through clinic pharmacologic studies of opioid drugs. Dr. Foley has received numerous awards and honors for her work. She received the Distinguished Service Award and the Humanitarian Award from the American Cancer Society, the David Karnovsky Award from American Society of Clinical Oncology, and the Frank Netter Award from the American Academy of Neurology.

Prof John O’Leary

**“A Molecular Algorithm for Cervical Cancer”**

Professor John O’Leary (M) received his MB, BCh, BAO degree from the National University of Ireland at Cork in 1987. He subsequently received a BSc and MSc from the National University of Ireland at Cork in 1989 and 1991. He received his doctoral degree MD in 1993: his thesis focussing on human papillomavirus in female genital tract neoplasia. In 1996, he was awarded a Ph.D./D.Phil. from Oxford University: his thesis focussing on the newly discovered Human Herpes Virus 8 (HHV8). He was previously lecturer in Pathology at Oxford University, Visiting Professor of Pathology, Cornell University Medical School, NY, USA and Consultant Pathologist, The Coombe Women’s Hospital and is currently Professor of Pathology, Trinity College Dublin, Ireland. He is founder of the ICSRC (Irish Cervical Screening Research Consortium).

Prof Tom Cotter

**“Cell Survival Strategies Used by Tumour Cells”**

Tom Cotter, graduated with a B.Sc. in Biochemistry from University College Cork before completing a Ph.D. at the University of Oxford where he was a Pirie-Reid Scholar. Following positions in the USA (Post-Doctoral & subsequently Fullbright visiting Professor) he has been Professor of Biochemistry at University College Cork since 1995. Professor Cotter was awarded the Boyle Medal for his work in 1999 and was elected to membership of the Royal Irish Academy in 2005. His main research interests are in understanding cell death & survival mechanisms. Prof. Cotter is also co-founder of two start-up biotechnology companies. He has served on the Boards of Science Foundation Ireland, Health Research Board of Ireland and is currently a Board Member of Cancer Research Ireland and Chairs the Board of Meridian Theatre Company.

**BIOGRAPHIES**

Prof Laura Beretta

**“Hepatitis C virus and hepatocellular carcinoma”**

Laura Beretta is an Associate Member at the Fred Hutchinson Cancer Research Center in Seattle and holds a doctorate in Molecular and Cellular Pharmacology from the University of Paris VI, France. Dr. Beretta studies the progression of liver disease in patients with chronic hepatitis C virus infection. She uses genomic and proteomic approaches to characterize the virus-host interaction and to identify markers for risk evaluation, early detection and treatment response for hepatocellular carcinoma.

Dr David Waugh

**“Therapeutic Potential of Targeting CXC-Chemokines within the Tumour Microenvironment of Prostate Cancer”**

Dr Waugh is a Reader of Molecular Pharmacology in the Centre for Cancer Research and Cell Biology at Queen's University Belfast. He also has a key role in the development of postgraduate education and training within the Centre. His research is focused on determining the molecular and cellular events regulated by CD44 and CXC-chemokines, with regard to their impact on metastasis of breast and prostate cancer to the bone. He has recently been elected as Secretary to the Irish Association for Cancer Research.

Dr Sam Hanash

**“The value of Proteomics to the Clinical Perspective in Cancer”**

Dr. Hanash is program head for Molecular Diagnostics at the Fred Hutchinson Cancer Research Center in Seattle, Washington. Dr. Hanash's interests and expertise focus on the development and application of integrated approaches to the molecular profiling of cancer, with particular emphasis on proteomics. He has been a program principal investigator for several multi-investigator collaborations aimed at biomarker discovery and validation using proteomics. Dr. Hanash has organized and participated in several workshops and initiatives related to diagnostics and proteomics. He is the inaugural president of the Human Proteome Organization which is involved in a number of scholarly activities, notably developing standards for the field of proteomics.

## BIOGRAPHIES

Dr Brian Mouton



Dr Brian Moulton was educated at University College Dublin, Trinity College Dublin and the University of East London. After completing a doctorate in Psychopharmacology he moved away from the bench in 1992 into the arena of commercial clinical trials management. He joined ICORG the national cancer clinical trials group in 1997 and subsequently became the Chief Executive Officer of the group in 2000. Under his management ICORG has established itself as an internationally recognised and respected high quality clinical trials group which has opened more than 100 trials and made a research option available to more than 3000 Irish patients. Dr Moulton's research interests include the changing European regulatory environment, the many ethical and practical challenges facing academic research on a European and international level and the cooperative group model of international clinical research collaboration. In 2003 Dr Moulton was appointed to the EU steering committee for cancer research management which sought to find practical solutions to the difficulties of the impending new EU clinical trial legislation and succeeded in compiling the first comprehensive review of European funding of cancer research. In more recent times he has been a member of the Irish Governments cancer biobank advisory panel.

Prof Mark Lawler



Professor Mark Lawler is Associate Professor In Experimental Haematology/ Oncology, Trinity College Dublin and Chief Molecular Geneticist and Director of the Cancer Molecular Diagnostics Laboratory St James's Hospital. He has an active research group working on the molecular basis of cancer, with emphasis on biomarker discovery and novel anti-cancer approaches. He has been honoured with numerous awards including the Vander Molen Prize for Leukaemia Research, the Ulster Cancer Foundation Lecture and he has received both the St Lukes Medal and the Graves Medal for research. He is currently President of the Irish Association for Cancer Research. He is a member of the Ireland/Northern Ireland/ National Cancer Institute Cancer Consortium Scientific Advisory Group and he has recently taken the Chair of the Scholar Exchange Programme. He is a founder member and one of the coordinators of the MSc in Molecular Medicine, TCD. He is founder and Chairperson of the highly successful Cancer Conference which has now become an annual event on the calendar. Professor Lawler is Director of Post-graduate Teaching and Learning in the School of Medicine, Trinity College Dublin and has a significant commitment to scholar exchange.

Prof Patrick Johnston



Professor Patrick Johnston was appointed Professor of Oncology at Queen's in 1996. Since then he has led the development of a comprehensive cancer centre for Northern Ireland, encompassing a £65 million state-of-the-art clinical cancer centre at Belfast City Hospital and a £25 million major cancer research complex - the Centre for Cancer Research and Cell Biology at Queen's of which he was Director until August 2007. He was appointed Director of the Institute of Health Sciences and Dean of the School of Medicine and Dentistry at Queen's University Belfast in September 2007. Prof. Johnston received his MB BCH degree in medicine with distinction from University College Dublin in 1982. This was followed by an



## BIOGRAPHIES

**Prof Patrick Johnston**  
continued

internship and senior house officer internal medicine training at the Mater and St James's University teaching hospitals also in Dublin until 1985. From 1985-1987 he pursued his initial training in Oncology and Haematology in the Mater Hospital, University College Dublin, during which time he attained his doctoral degree. In 1987 he then obtained a fellowship at the National Cancer Institute, NIH, USA where he began to pursue further clinical training in medical oncology and his post-doctoral studies in molecular pharmacology and drug development. During this time he defined the regulation and clinical relevance of the nucleotide synthetic enzyme thymidylatesynthase (TS); a key cancer therapeutic target and completed a number of phase I clinical studies using antifolate therapies such as tomudex in patients. As a result of this work he was promoted to senior investigator status at the NCI in 1991. During this time, he also received the Young Investigator Award from the American Society of Clinical Oncology and the Technology Award from the National Cancer Institute. In 1996 he was appointed Professor of Oncology at Queen's University Belfast and since then he has led the development of a comprehensive cancer centre for Northern Ireland encompassing a state-of-the-art clinical cancer centre (£65 million) which opened in March 2006, and also a £25 million major cancer research complex (the Centre for Cancer Research and Cell Biology) at Queen's which has as its major emphasis translational research. This interdisciplinary research centre, which houses over 300 researchers from all over the world, opened in July 2007. Professor Johnston has also led the development of a number of international research collaborations, most notably the creation of the NCI-All Ireland Cancer Consortium which was signed in 1999 and renewed in 2006. He has continued his research work utilising genomic-based technologies to define the transcriptional changes induced in tumours by cytotoxic agents such as 5-FU and Oxaliplatin and identifying groups of genes whose expression may predict for response or toxicity to these therapies. He has also identified that the extrinsic apoptosis pathway regulated by Fas/Apo1 and c-FLIP is important in mediating cell death to chemotherapy and are currently developing new strategies to target this pathway.

**Dr Robert O'Connor**

Robert O'Connor, Ph.D, is a Senior Programme Leader in Translational Cancer Pharmacology at the National Institute for Cellular Biotechnology at Dublin City University. Dr. O'Connor's research straddles the interface of laboratory and clinic using cellular modelling, toxicology and pharmacokinetic analysis to identify rational combination treatments for advanced/resistant cancers and extending these scientific evaluations into Phase I and Phase II clinical trials. Dr. O'Connor is a council member of the Irish Association for Cancer Research (IACR), member of the scientific and translational committees of the All Ireland Cooperative Oncology Research Group (ICORG).

**Dr Marie Laffroy**



Dr Marie Laffroy is Assistant National Director for Strategic Health Planning with the Population Health Directorate of the HSE. She previously worked as Regional Director of Public Health. She is a member of the National Cancer Screening Service Board.

## BIOGRAPHIES

Dr Harry Comber



Dr Comber has been Director of the Irish National Cancer Registry since its beginning in 1992. He received his undergraduate degree in Chemistry at University College, Cork and, after being awarded a PhD at the Institute of Cancer Research in London, studied medicine in Cork and worked there as a family doctor for twelve years. His research interests are in the epidemiology of early detection of cancer, its treatment and survival.

Dr Norma Cronin

Norma Cronin qualified as a general nurse and midwife in Ireland and holds a Higher Diploma in Public Health. For the past fifteen years she has worked in the field of cancer prevention and health promotion at the Irish Cancer Society. In her current position as Health Promotion Manager, Tobacco Control, she has overall responsibility for tobacco control initiatives for the Irish Cancer Society. In collaboration with the relevant agencies, she played a major role in ensuring the effective implementation of Ireland's Smoke Free at Work legislation; and has presented nationally and internationally on this groundbreaking initiative. Norma established and manages Ireland's National Smokers' Quitline which is an initiative of the Irish Cancer Society in partnership with the Health Service Executive. She is also a Board Member of ASH Ireland and has recently been appointed to the Board of Office Tobacco Control (OTC).

Dr Seamus O'Reilly

Dr Seamus O'Reilly is a consultant Medical Oncologist at Cork University, Mercy University and South Infirmity Victoria Hospitals. Member Irish Clinical Oncology Research Group where he co chairs the Gastrointestinal Disease subgroup. He is a graduate of University College Galway, trained in Medical Oncology at Johns Hopkins Hospital Baltimore MD.

Dr Paul Browne

Paul Browne is a Consultant Haematologist at St. James's Hospital and a Lecturer at the Department of Haematology, Faculty of Health Sciences, University of Dublin. He received his medical degree at the University of Dublin, Trinity College in June 1986. He undertook a fellowship in haematology at the University of Minnesota Medical School, Minneapolis, United States from 1992 to 1995. His research interest includes the molecular pathology of multiple myeloma. He is currently the chairman of the St James's Hospital Medical Board and vice chair of the Irish Clinical Oncology Research Group.

Prof Dermot Kelleher



Prof Dermot Kelleher MD, FRCP, FRCPI, F Med Sci, graduated in Medicine from TCD in 1978 and completed specialist training in Gastroenterology in Dublin. He subsequently received a Fogarty Scholarship for a research fellowship at University of California San Diego. In 1989 he was appointed as a Wellcome Senior Fellow in Clinical Science at Trinity College Dublin and was subsequently appointed as Professor of Clinical Medicine in 2001. Professor Kelleher's research has focussed on the cell biology of immune responses both in terms of basic lymphocyte function and in relationship to mucosal immunology. His research has been focussed on the immune response to many of the leading causes of infectious disease worldwide. Prof Kelleher in collaboration with Prof Hugh Brady at UCD obtained collaborative grant funding to establish the Dublin Molecular Medicine Centre a joint venture between the three



## BIOGRAPHIES

**Prof Dermot Kelleher**  
continued

major medical schools in Dublin which provides a physical infrastructure for major developments in medical biotechnology in Ireland. In this context Prof Kelleher obtained funding for the construction of and is the inaugural director of the Institute of Molecular Medicine, a TCD facility at St James's Hospital. More recently, he has been successful in obtaining funding for a Wellcome Trust HRB funded Clinical Research Centre at St James's Hospital.

**Prof Noel Lowndes**

Upon graduating with his BA (Mod) degree in Genetics from Trinity College Dublin, Ireland in 1983, Professor Lowndes obtained his PhD from the University of Glasgow in 1988. He then joined Lee Johnston's Laboratory at the Medical Research Council's National Institute for Medical Research (NIMR), London. In 1993 Professor Lowndes established his laboratory at the Imperial Cancer Research Fund (now Cancer Research UK). Since 2001, he is the head of the Department of Biochemistry, and leads the Genome Stability Laboratory at the National University of Ireland Galway. Professor Lowndes' has built an international reputation as an expert on the mechanisms of cell cycle control and, more recently, DNA damage-dependent checkpoint regulation. In addition to his scientific track record and since his recent move to Galway, Professor Lowndes has played a pivotal role in positioning NUI Galway at the forefront of cancer biology within Ireland. In particular, he has led the development of an internationally recognised and expanding cluster of excellence in cell cycle and genome stability studies.

**Prof Arnold Hill**

Professor Hill is Professor of Surgery and Chairman of the Department of Surgery at The Royal College of Surgeons in Ireland and at Beaumont Hospital, Dublin. He graduated from University College Dublin. He did a two year basic research fellowship with Dr John Daly at The Hospital of the University of Pennsylvania and The New York Hospital / Cornell Medical Center in the United States. He returned to Ireland to do his Senior Registrar training on the National Training Programme in Ireland. He also did a clinical fellowship in Surgical Oncology at Memorial Sloan Kettering Cancer Center in New York prior to taking up his first consultant appointment at St Vincent's University Hospital in Dublin. His clinical interests are in the area of breast cancer and melanoma. His laboratory research interests are in the transcriptional control of breast cancer in particular the role of the coregulatory proteins in endocrine resistance. In January 2006, Professor Hill took up Chair of Surgery at The Royal College of Surgeons of Ireland and transferred his clinical practice to Beaumont Hospital, Dublin, the principle teaching hospital of the RCSI Ireland.

**Prof Cormac Taylor**

Cormac Taylor graduated with a PhD in Pharmacology from University College Dublin (UCD) in 1996. He then spent 5 years as a postdoctoral fellow in Harvard Medical School before returning to the School of Medicine and Medical Science, UCD where he is now Associate Professor of Cellular Physiology. His current research is directed towards expanding our understanding of the mechanisms by which hypoxia regulates transcriptional and non-transcriptional events in tumor cells. Recent work has concentrated on the regulation of global gene expression in response to hypoxia and the modification of transcriptional regulators which underlies the induction of such events.

## BIOGRAPHIES

Dr Graham Pidgeon

Dr. Graham Pidgeon graduated from DCU with a degree in Analytical Science and obtained a Ph.D. in Cancer Research from the Dept. Surgery, RCSI/DCU in 2000. Awarded an American Cancer Foundation Fellowship, he worked as a postdoctoral research fellow at Wayne State University, Michigan with Prof. Kenneth Honn on the regulation of prostate cancer survival by bioactive lipids. In 2002 he returned to Ireland as a postdoctoral fellow in the Dept. Clinical Pharmacology at RCSI. He was awarded a HRB postdoctoral fellowship in 2004, and joined Dr. Ken O'Byrne in the Thoracic Oncology Research Group at the Institute of Molecular Medicine at TCD/St. James as research lecturer. He developed his own research group focused on the regulation of VEGF-mediated survival pathways by COX and LOX in lung cancer and combining inhibitors of these pathways with conventional chemotherapy. He was appointed senior lecturer in Dept. Surgery at TCD/St. James in Jan 2007 and has expanded these research areas into other prevalent solid malignancies, including oesophageal and colorectal cancer. His current research is focused on the role of bioactive lipid enzymes including cyclooxygenase and lipoxygenase in the growth and metastasis of oesophageal and lung cancer. Other aspects of his research include the role of downstream mediators of cyclooxygenase signalling in thrombosis and angiogenesis in cancer.

Mr John McCormack



Mr John McCormack was appointed CEO of the Irish Cancer Society in October 2002. He was formerly Company Secretary and Financial Controller with the Society, is a member of the Institute of Certified Public Accountants in Ireland and holds an MBA from Dublin City University. In 1991, he founded the Irish Charities Tax Reform Group which has lobbied successfully for the introduction of tax relief on corporate donations. Two of Mr McCormack's key areas of interest are men's health and palliative care. In November 2003, he was instrumental in launching the first ever Men's Cancer Action Week. This initiative is now an annual event undertaken to raise awareness among men of the steps they can take to help reduce their risk of developing common cancers and to promote the benefits of early detection for long-term survival. Mr. McCormack is also involved in lobbying for the implementation of a nationwide cervical cancer screening programme and for the implementation of the recommendations of the 2001 Report of the National Advisory Committee on Palliative Care. In addition, he led the Irish Cancer Society in hosting the 4th World Conference of Cancer Organisations in November 2004.

Prof Cliona O'Farrelly

Cliona O'Farrelly is currently Professor of Comparative Immunology in the School of Biochemistry and Immunology at Trinity College Dublin. She is Chair of Cancer Research Ireland, a member of the Irish Council of Bioethics and a committee member of the Irish Society of Immunology. She obtained her primary degree in Microbiology and a PhD in Immunology from Trinity College in 1977 and 1982 respectively. After postdoctoral positions at St. James's Hospital Dublin and Sussex University in the UK, Cliona became Lecturer on Biology at Harvard University from 1997-1990. On her return to Ireland in 1990, Cliona was Wellcome Research Fellow at Trinity College before taking up Directorship of the Research Laboratories at St. Vincent's University Hospital from 1993-2007. A recipient of the

**BIOGRAPHIES**

**Prof Cliona O'Farrelly**  
continued

Irish Research Scientists' Association Gold Medal, the Graves medal and the Conway medal, Cliona O'Farrelly also was President of the Irish Society of Immunology from 2000-2007 and a Core Conway Investigator at the Conway Institute, University College Dublin. Currently, Cliona and her research group are interested in Comparative Immunomics which uses combined in silico and molecular technologies to examine genes and proteins of the innate and adaptive immune systems from different species and in different organs.

**Prof Liam Gallagher**

Prof. Gallagher originally graduated from the Department of Biochemistry, UCD in 1993 with a 1st Class Joint Honours degree in Molecular Genetics and Biochemistry. Subsequently, he obtained a PhD in Molecular and Cellular Biology from the Cancer Research UK Beatson Laboratories in Glasgow. In 1997, he moved to Paris to undertake a Marie Curie Individual Fellowship at Rhone-Poulenc Rorer (currently Sanofi-Aventis). Afterwards, he returned to Ireland upon receipt of an Enterprise Ireland Post-Doctoral Fellowship (1999-2000) and, subsequently, a Marie Curie Return Fellowship (2000-2001). In 2001, he was employed in a permanent capacity as College Lecturer at UCD within the former Department of Pharmacology. In 2005, he was appointed Senior Lecturer within the UCD School of Biomolecular and Biomedical Science and was promoted to Associate Professor of Cancer Biology in 2006. Prof. Gallagher is also a Principal Investigator at the UCD Conway Institute. In 2007, he co-founded OncoMark Ltd., which is a private company centred on the development and application of biomarker panels and associated technologies, on both tissues and biological fluids ([www.oncomark.com](http://www.oncomark.com)). A major of focus of Prof. Gallagher's research work is the identification and validation of candidate biomarkers of breast cancer and melanoma, with particular emphasis on translation of transcriptomic and proteomic datasets into clinically relevant assays. In addition, his team utilises lentiviral-based approaches to investigate the functional relevance of candidate tumour progression-associated genes at both in vitro and in vivo levels, as well as engages in preclinical evaluation of novel anti-cancer agents.

## REGIONAL ONCOLOGY PROGRAMME OFFICE

### Introduction

The Regional Oncology Programme Office (ROPO), HSE - South Western Area whose principal remit of the Office is to help facilitate and co-ordinate cancer initiatives across a broad spectrum of activity involving primary, secondary and tertiary care. The HSE Southwest Area manages approximately 3,000 new cancer cases each year, accounting for about 15% of the national workload. It contains national centres in Adult and Paediatric Bone Marrow Transplant Units, Paediatric Cancer, Plastics and Reconstruction, Maxillofacial Surgery, and Cardio-thoracic surgery, as well as major supraregional services in oesophageal, pancreatic, head and neck, gynaecological and urological cancer.

The Regional Oncology Programme Office is a resource to enable and mobilise efforts in cancer care services among institutions in the region, including facilitating educational initiatives, expanding compatible cancer audit information systems. In this way, ROPO functions as a focal point for building strong collaborative relationships with Regional and National bodies. This office works under the guiding principles of 'A Strategy for Cancer Control in Ireland 2006'. Some of the key regional initiatives include:

#### 1. Health Promotion

ROPO has developed a number of health promotion programmes. These includes 'Your Health is your Wealth' and 'Wise up, its your life too!' which were developed in partnership with the Marie Keating Foundation and the Irish Cancer Society.

#### 2. Early Detection and Screening

The development of General Practitioner Referral Guidelines for Cancer is nearing completion by the ROPO. This aims to provide GPs with clear guidelines on how to refer suspected cancer patients to the cancer multidisciplinary teams within the region's hospitals.

#### 3. Direct Service Provision

The ROPO supports the teams who provide palliative care, and managing nursing, social, and other aspects of cancer care. The office has worked closely to develop palliative care booklets and map out palliative care services within the region. Further plans include the development of electronic cancer referral forms in conjunction with the Healthlink ([www.healthlink.ie](http://www.healthlink.ie)) project. This will streamline the cancer referral process and provide two way communication between the GP and the cancer care consultant.

#### 4. Communication

A key function of ROPO is enabling communication, and this has been progressed through the work of the office on the annual International Cancer Conference, information meetings for general practitioners, and oncology nursing meetings. The Office has also helped in developing written and DVD material for our patients.



## SPONSORS

We would like to acknowledge and thank the following sponsors for their kind contribution to the Cancer 2008 Conference

### Gold Sponsors

Irish Cancer Society  
National Cancer Institute (NCI)

### Silver Sponsors

Pfizer  
Roche  
Novartis  
The Department of Health and Children  
Health Research Board

### Bronze Sponsors

Astra Zeneca  
Bayer Schering Pharma  
Bristol Myer Squibb  
Cephalon  
Ely Lilly  
Glaxo Smith Klein  
Marie Keating Foundation  
Varian

### Other Contributors

Baxter

**SPONSORS**

**Gold Sponsors**



**Silver Sponsors**



**Bronze Sponsors**



**Other Contributors**





## SPONSORS

### Irish Cancer Society

The Irish Cancer Society, is the national charity dedicated to eliminating cancer and improving the lives of those living with cancer. Its main areas of focus are the delivery of health promotion and cancer prevention campaigns and programmes, the delivery of free nationwide patient care services for people with cancer and their families and the funding of pre-clinical and clinical cancer research.

The hospital and community based patient care services are the flagship services run by the Society. The main services include funding of Oncology Liaison Nurses in major cancer hospitals across the country, funding night nursing for patients in their homes at the advanced stage of their illness and funding Home Care Nursing teams. The Society also operates the National Cancer Helpline (Freefone 1800 200 700) which is staffed by specialist cancer care nurses. The National Cancer Helpline handles approximately 7,000 calls per year and offers advice, information and support on all aspects of cancer prevention, diagnosis, treatments and support.

The Society is the largest single voluntary supporter of cancer research in Ireland and funds research to the tune of approximately €2.6 million per year in Irish hospitals and universities. All cancer research activities are managed through Cancer Research Ireland (CRI), the research division of the Irish Cancer Society. The Society is financed entirely by voluntary

contributions from the public and receives no government funding for the development and delivery of its services. This allows the Society to pursue new and innovative services for patients with cancer outside of government policy.

We rely on thousands of dedicated volunteers from around the country to help with our fundraising activities, the largest of which is our annual Daffodil Day.

### National Cancer Institute

The National Cancer Institute (NCI) is a component of the U.S. National Institutes of Health and is the U.S. Government's principal agency for cancer research and training. The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. Specifically, the NCI supports and coordinates research projects conducted by universities, hospitals, research foundations, and businesses throughout the U.S. and abroad through research grants and cooperative agreements; conducts research in its own laboratories and clinics; supports education and training in fundamental sciences and clinical disciplines for participation in basic and clinical research programs and treatment programs relating to

cancer through career awards, training grants, and fellowships; supports research projects in cancer control and a national network of cancer centers; collaborates with voluntary organizations and other national and foreign institutions engaged in cancer research and training activities; encourages and coordinates cancer research by industrial concerns where such concerns evidence a particular capability for programmatic research; collects and disseminates information on cancer; and supports construction of laboratories, clinics, and related facilities necessary for cancer research through the award of construction grants. The *Ireland Northern Ireland National Cancer Institute Consortium* encompasses the Departments of Health in Ireland, North and South, and the Departments of Health and Human Services in the US ([www.allirelandnci.org](http://www.allirelandnci.org)) has created training opportunities and collaborative research programmes for a large number of professionals involved in cancer care and cancer research throughout the island of Ireland.

### Pfizer Oncology

Pfizer Oncology is committed to advancing the scientific understanding of cancer and to bringing new medicines to millions of cancer patients. Oncology is a research priority for Pfizer, with over 12 percent of the company's research and development investment devoted to discovering and developing innovative therapies for treating breast, colorectal, renal cell carcinoma,

## SPONSORS

gastrointestinal stromal tumour and other cancers.

### Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system. Roche employs roughly 75,000 worldwide and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional information about the Roche Group is available on the Internet at [www.roche.com](http://www.roche.com).

### Novartis Oncology

At Novartis Oncology, our primary goal is to research and develop new and more effective ways to treat cancer - in essence, to bring our vision of research to life. Novartis Oncology is exploring various novel compounds in all phases of development, and is pioneering signal transduction inhibition, antiangiogenesis,

novel cytotoxics, iron chelation, and other exciting areas that are likely to change the way cancer is treated in the future.

Our mission is to become the world's premier oncology company by consistently discovering, developing, and producing broadly available novel therapies that improve and extend the lives of patients with cancer. Through our rich, broad, and deep pipeline, we are poised to shape cancer research and treatment tomorrow.

### The Health Research Board

The Health Research Board (HRB) is the lead agency supporting and funding health research in Ireland. We provide funding, maintain health information systems and conduct research linked to national health priorities. Our aim is to improve people's health, build health research capacity, underpin developments in service delivery and make a significant contribution to Ireland's knowledge economy.

Our current investment to underpin research that will help tackle Cancer is €25.9 million. We work closely with the Ireland - Northern Ireland - National Cancer Institute Cancer Consortium which aims to reduce the incidence and mortality of cancer on the island of Ireland.

### Astra Zeneca

AstraZeneca is a major international healthcare business engaged in the research, development,

manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of \$26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4 Good Index.

### Bayer Schering Pharma

BSP is one of the top ten pharmaceutical specialists in the world and aims to discover and manufacture innovative products that will improve human health. Its products enhance well-being and quality of life by diagnosing, preventing and treating disease.

Bayer Schering Pharma has six business units: Oncology, Diagnostic Imaging, Haematology/Cardiology, Primary Care, Specialty Therapeutics and Women's Healthcare.

### Bristol-Myers Squibb

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

### Cephalon

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and



## SPONSORS

commercialisation of innovative products in four core therapeutic areas: oncology, central nervous system, pain and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe.

The Cephalon European headquarters and pre-clinical development centre are located in Paris, France. Cephalon Europe markets more than 30 products in four therapeutic areas: central nervous system, pain, primary care and oncology.

Among its oncology products, Cephalon Europe markets MYOCET(R) (liposomal doxorubicin) which is indicated in combination with cyclophosphamide for first-line treatment of metastatic breast cancer; TARGRETIN(R) (bexarotene) for advanced cutaneous T-cell lymphoma; and TRISENOX for relapsed or refractory acute promyelocytic leukemia.

Today, Cephalon is poised for a new level of growth, with an expanded international presence, a diverse product portfolio, and medications with even greater therapeutic potential.

### Eli Lilly

Lilly is a leading innovation-driven pharmaceutical corporation. We are developing a growing portfolio of best-in-class, first-in-class pharmaceutical products by applying the latest research from our own worldwide laboratories, by collaborating with eminent scientific

organizations, by making use of the most up-to-date technological tools and by providing exceptional service to our customers. Through these internal programs and external initiatives, we're seeking answers for some of the world's most urgent medical needs. As our products save and improve lives, they also save overall health care costs: they are often less expensive than other forms of health care, such as surgery and hospitalization.

### Glaxo Smith Klein

GSK employs over 1600 people across 4 sites in Ireland: Dublin is the commercial headquarters, responsible for marketing and sales of both pharmaceutical and consumer products and Clinical trials, regulatory affairs and medical information. GlaxoSmithKline Cork employs over 600 people is a strategic global new product introduction site and is currently the primary production site for a number of products treating illnesses such as Breast Cancer, HIV, and Parkinson's Disease. GSK Dungarvan employs over 700 people across two manufacturing sites and is engaged in the production of a range of over-the-counter (OTC) pharmaceuticals as well as an oral care facility.

### Marie Keating Foundation

"Following their mother Marie's death in 1998 each member of the Keating family promised that they would do everything they could to bring an end to breast cancer. They committed to provide all women and their

families with the necessary information to prevent cancer or detect it at its earliest stages. Their collective aim was to "enlighten not frighten". The Marie Keating Foundation is the realisation of a family's dedication - it is a promise to themselves in action. Through three mobile information units the Foundation's dedicated nurses have enlightened almost 60,000 people of the causes and risk factors of breast and other cancers. "Men Keeping Fit" is now a successful annual campaign and has significantly raised awareness among men of testicular and prostate cancer.

The Foundation finances other areas of need in cancer care. Monies raised help to refurbish hospital oncology waiting rooms in making them more comfortable for patients. A comfort fund for those in financial difficulty as a result of their illness provides immediate assistance, when required. The Foundation is committed to raising awareness among young people in schools of cancer and its prevention. The Foundation provides its services free of charge."

### Varian

Varian Medical Systems is the world's leading manufacturer of integrated cancer therapy systems, which are treating thousands of patients per day. The company is also a premier supplier of X-ray tubes and flat-panel digital sub systems for imaging in medical, scientific, and industrial applications. For more information, visit [www.varian.com](http://www.varian.com)

**NOTES**



**NOTES**

**NOTES**